Toxicogenomics Data: The Road to Acceptance by Freeman, Kris
use of toxicogenomics data in government
risk assessment and regulatory decision and
policy making. These issues include the
many challenges that remain to be resolved
before these tools find direct application in
chemical risk assessment, says David Eaton,
chair of the NRC committee and director of
the NIEHS Center for Ecogenetics and
Environmental Health at the University of
Washington. 
Because of the expense involved in run-
ning microarray experiments, including the
costs of analyzing data, microarrays are gen-
erally not used in detailed dose and time-
course studies, says Eaton. As a result, cur-
rent microarray data often provide a limited
snapshot of information that Eaton says can
be very useful in terms of generating hy-
potheses about mechanisms of exposure,
although the application of such informa-
tion for regulatory purposes is fraught with
uncertainty.
Government’s Take on Microarray Data
“We think there are powerful uses for genet-
ic data, including microarray data, in the
real world of drug safety, to both test prod-
ucts and do ‘forensic’ studies—that is, go
back and investigate safety problems after
marketing,” says CDER director Janet
Woodcock. “In cases of some adverse drug
effects, companies may be able to go and
look for specific genotypes that are distinc-
tive and at risk for an adverse event.” Agency
regulators, she adds, hope that intractable
drug toxicity problems, such as hepatotoxic-
ity, could be solved through microarray or
gene expression technologies.
EPA representatives hope that microar-
ray technology, along with proteomics and
metabolomics experiments, will help the
agency better screen the vast number of
chemicals it is mandated to regulate. Using
traditional tests, it can easily take 3–4 years
and $20 million to test the toxicity of a pes-
ticide, says Robert Kavlock, director of the
Reproductive Toxicology Division in the
EPA Office of Research and Development.
“In the long run, we expect that the use of
‘omics’ technologies can be applied to a
variety of bioassays, some in vitro, some in
vivo, that will help us prioritize chemicals
for testing in the more lengthy, expensive,
and animal-intensive testing batteries, and
perhaps even to guide selection of which
tests should be done within those batter-
ies,” says Kavlock. “By doing so, we will
become more efficient and effective in our
utilization of animal tests.” 
“Genomics won’t replace animal testing,
not yet,” adds William Benson, director of
the Gulf Ecology Division of the EPA
National Health and Environmental Effects
Research Laboratory. “But we hope it will
allow us to use animals more wisely.” 
Microarrays and other “omics” technolo-
gies could also be used in environmental
monitoring, such as water testing. As the
technology decreases in cost, local regulators
may be able take a microarray chip into the
field, apply water samples, and get an answer
right there regarding the presence of bacte-
ria, viruses, and other pathogens, according
to Kerry Dearfield, senior scientist for sci-
ence policy in the EPA Office of the Science
Advisor. Dearfield, along with  Benson and
Kathryn Gallagher, science policy council
staff in the Office of the Science Advisor,
wrote a March 2004 EPA draft white paper
on the impact of genomics technologies on
EPA regulatory activities. 
Although both the EPA and the FDA
have discussed possible uses of microarray
data, only the FDA has issued requirements
for the submission of such data. At press
time the agency was working on a final ver-
sion of its “Guidance for Industry: Pharma-
cogenomic Data Submission,” released in
draft form in November 2003. Under the
draft guidance, companies may be required
to submit microarray data used to deter-
mine differential dosing of a medication by
genotype during development (a require-
ment that applies to animal testing as well
as human clinical trials). The guidance also
encourages, but does not require, compa-
nies to develop suitable genetic tests for
such medications to allow physicians to
determine if a drug is appropriate for a
given patient.
“The centers for drugs and devices are
working together for the development of
drug–device combinations,” says Atiqur
Rahman, acting deputy director for the
CDER Division of Pharmaceutical Evalua-
tion 1. “If a drug’s approval becomes based
upon a specific test, you can’t approve the
drug unless the test is available.” 
The draft guidance also encourages, but
again does not require, voluntary submission
of microarray data from exploratory studies
such as experiments to screen multiple com-
pounds for possible toxicity or efficacy.
Companies are also asked to supply research
data resulting from general gene expression
analyses in cells, animals, and humans, as
well as analysis of single-nucleotide poly-
morphisms in trial participants.
In addition, all data on “known valid
biomarkers,” including those collected dur-
ing exploratory studies, must be submitted
to the FDA. Although the guidance does
not specify the types of biomarkers that
must be submitted, Woodcock clarifies that
the agency is mainly interested in so-
called safety biomarkers, those that indi-
cate toxicity. “Companies don’t have to
submit any data on nonclinical efficacy
biomarkers,” she says.
Currently, the EPA’s official dictum on
the regulatory use of microarray data is
limited to a four-page “Interim Policy on
Genomics” issued in June 2002. The
interim policy states that microarray data
are expected to be valuable, and that they
“may be received as supporting informa-
tion for various assessment and regulatory
purposes, e.g., identifying an environmen-
tal stressor’s mode or mechanism of
action.” But the interim policy does not
provide any details on potential required
submissions of gene expression data. There
is no current effort at the EPA to expand
or update the interim policy.
What It Means for Industry
Industry response to these regulatory efforts
ranges from enthusiasm to extreme caution.
“Some companies will not test a drug with a
microarray experiment that has any chance
of becoming part of a regulatory package,”
says Kurt Jarnagin, vice president for biolog-
ical sciences and chemical genomics at
Iconix Pharmaceuticals. “And then there are
companies who view [submission of micro-
array data] as a positive, who say the FDA
gets more information, we get more infor-
mation, and we might find a positive aspect
to our drug that we didn’t know about.” 
There are already a number of drugs
approved for people with specific genetic
variations. Most are powerful cancer drugs
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safety problems after marketing.for which the boundaries between efficacy
and toxicity are narrow. One example is
imatinib mesylate (trade name Gleevec),
which is approved for patients with a specif-
ic type of leukemia characterized by a chro-
mosomal rearrangement in the cancerous
cells. Another example is trastuzumab (trade
name Herceptin), an intravenous treatment
for advanced metastatic breast cancer.
Trastuzumab is effective in treating tumors
that produce excess amounts of the HER2
protein, a tyrosine kinase receptor.
In addition to determining who is most
likely to respond to a drug, genetic studies
could also be used to screen out those most
susceptible to toxic side effects. One exam-
ple is the case of the lung cancer drug gef-
tinib (trade name Iressa), which inhibits a
tyrosine kinase that is overexpressed in
non–small cell lung cancer, the leading cause
of cancer deaths in the United States. After
the drug was approved, the FDA received
reports of severe, sometimes fatal, toxicity in
0.3–2.0% of patients receiving the drug. In
addition, during clinical trials, the drug was
effective in only 10–19% of persons with
non–small cell lung cancer. Preliminary
results published 20 May 2004 in the New
England Journal of Medicine indicate that the
drug is effective only in people who have
heterozygous mutations in the tyrosine
kinase epidermal growth factor receptor,
coded by the gene EGFR.
Microarray data were not submitted
during the approval process for any of these
drugs, but could be used in the future to
help develop population-specific treat-
ments, according to Rahman. “A certain
type of gene expression constituting a gene
signature may help determine if a person is
a candidate for treatment with a particular
drug and is likely to respond to the thera-
py,” he says.
In contrast to the pharmaceutical indus-
try, “the chemical industry is not chomping
at the bit to use toxicogenomics data,”
claims Linda Greer, director of the Natural
Resources Defense Council public health
program and a member of the NRC com-
mittee. “The status quo works better for
them rather than a system where chemicals
can be screened systematically,” she adds.
More than 90% of the industrial chemicals
in commerce have not been tested for their
toxicity, Greer says, and better screening
might cause increased scrutiny of such com-
pounds under the Toxic Substances Control
Act (TSCA) and the Federal Insecticide,
Fungicide, and Rodenticide Act (FIFRA). 
TSCA gives the EPA authority to
require reporting or testing of industrial
chemicals that may pose an environmental
or human health hazard, and to ban the
manufacture and import of chemicals that
pose high risks. However, the EPA is not
required—nor does it have the resources—
to perform extensive toxicity testing on
every industrial chemical available for sale
in the United States. Nor
can chemical companies
increase their profits by
determining genetically
based differences in re-
sponses to their general-
use products. “What we
sell is going to be out there
for the general population
to use, so we’re compelled
to protect the most sensi-
tive individual,” says
George Daston, a senior
toxicologist in the Central
Product Safety group of
Procter and Gamble. 
Risk exposure testing
for industrial chemicals can
also be less straightforward
than pharmaceutical test-
ing, increasing challenges
for both industry and the EPA. In contrast
to pharmaceuticals, which people generally
are exposed to at known doses for intended
biologic effects, environmental exposures to
industrial chemicals among the general
public are often quite low. In addition,
people are often exposed to mixtures of
compounds—for example, to several pesti-
cides from a piece of fruit, or to hundreds
of chemicals from swimming near a storm
sewer outfall. As a result, singling out the
effects of a single industrial compound can
be extremely difficult.
Nevertheless, some chemical companies
are conducting microarray experiments to
better understand mechanisms of toxicity,
which could lead to better risk assessment
information regarding susceptible popula-
tions, co-mixtures of chemicals, and low
levels of exposure, according to Greer and
Dearfield. For example, Greer says, micro-
array studies could build on research pub-
lished in the August 2004 issue of EHP
linking exposure to the complex mixtures
of disinfection by-products in drinking water
and low birth weight in children of women
with polymorphisms in the CYP2E1 and
C677T genes. 
Research such as this raises tough regu-
latory issues for the EPA, Greer adds—is the
EPA going to lower the standard of disin-
fection by-products to protect what might
turn out to be a substantial group, or are
they going to warn people and tell them to
get tested for genetic susceptibility? “Our
answer,” she says, “is that regulators need to
protect the most susceptible individuals.
You can’t tell people not to drink water or to
buy bottled water.”
Microarray data may also be able to
detect cellular activity in whole animals at
levels far lower than those that cause dis-
cernible changes such as tumors or weight
loss. In recent studies, researchers at the
Microarray Center of the NIEHS National
Center for Toxicogenomics (NCT) detected
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Drug data dilemma. Researchers and regulators alike are struggling
with the complexities—and uncertainties—of toxicogenomics data.
In the long run, we expect that the use of  
“omics” technologies can be applied to
a variety of bioassays, some in vitro,
some in vivo, that will help us prioritize   
chemicals for testing in the more lengthy, 
expensive, and animal-intensive 
testing batteries, and perhaps even 
to guide selection of which tests 
should be done within those batteries.
–Robert Kavlock, EPAearly indicators of mitochondrial damage
before any adverse effect could be detected
through traditional toxicity tests, says
Microarray Center director Richard Paules.
Such research doesn’t necessarily indicate
that such low doses are toxic, says Paules,
“but these gene expression changes could be
an indication that higher or longer expo-
sures have the potential to cause adverse
effects and should be studied more closely.”
Signatures of mechanisms of toxicity in
different species may also improve
researchers’ ability to compare the results of
animal studies and human health outcomes.
A chemical that causes, say, cancer in a rat
may not have the same effect in people if the
two species process the compound different-
ly. Such research is especially important for
the manufacturers of industrial chemicals,
who do not test their products on humans,
according to Jim Bus, director of external
technology at The Dow Chemical Company
and a member of the NRC committee.
Concerns Voiced
Although the use of microarray data and
acceptance by regulators can be beneficial
for pharmaceutical and other chemical man-
ufacturers, many industry representatives
still express concerns about the use of such
data by the FDA and the EPA. One of these
concerns—which runs contrary to the opti-
mism expressed by government—is that
submission of complex expression data will
slow processing and approval of applications
rather than streamline the process. Current
FDA approval times for regular drug appli-
cations are about 18 months, down from 30
months several years ago. Approval for pri-
ority drugs with a public health benefit,
such as AIDS medications, can take as little
as 6 months, according to Woodcock. 
Pharmaceutical and chemical compa-
nies have also expressed concern that the
FDA and the EPA might overreact to
microarray data. The primary issue, accord-
ing to Daston, is determining what type of
signature constitutes an adverse effect; the
challenge is to distinguish adverse respons-
es to a chemical exposure from homeostat-
ic responses—that is, normal changes that
may indicate a cell is disposing of a toxicant
in a way that will not lead to lasting dam-
age or that may not be related to the expo-
sure at all. 
Dearfield explains further: “Gene
expression changes all the time. You can
walk from a dark room into the sunlight,
and you’re going to get all kinds of genomic
signature changes. Is that bad? No—it’s the
way the body normally operates. You need
to sort out that kind of change from a
change caused by an adverse stressor.”
Similarly, there is concern
that the agencies will be “exces-
sively reactive” to single gene
changes, says Jarnagin. “Hypo-
thetically you do a microarray
expression on a potential drug’s
effect, and lo and behold, the
oncogene RAS is elevated five- or
tenfold. Using a [toxicoge-
nomics] database, you can see
that there are many approved
drugs that elevate RAS. Every
drug in our database elevates at
least one known oncogene. None
of these drugs are known to cause
cancer at therapeutic doses.”
Although the FDA draft
guidance states that voluntary
submissions of data will not be
used for regulatory purposes,
some companies still are reluctant
to part with the results of
exploratory microarray experi-
ments. Some companies fear that
proprietary data from one appli-
cation will be used to judge data
in another. In response,
Woodcock says, “We cannot apply propri-
etary data to another application; we can’t
make it public.” However, she says, regulators
do learn from the reviews they conduct. And
although they can’t directly compare data
from one application to another, problems
they see in one application might cause them
to more carefully scrutinize another applica-
tion with similar results.
Legal concerns include the potential for
being sued if microarray data that couldn’t
be interpreted at the time of submission
later turn out to indicate toxicity in some
people or under some conditions. The fear
of lawsuits is such that some companies
haven’t gone to the next stage in using
microarrays for evaluating the effects of
drugs under development, for either good or
bad effects, says Roger Ulrich, president of
Rosetta Inpharmatics, a subsidiary of Merck
and Company.
Manufacturers of industrial chemicals
are also concerned about EPA penalties. If a
company discovers a previously unknown
adverse effect for a given chemical, the com-
pany is required under TSCA to submit a
report to the EPA within a few days, says
Bus. The same is true if toxicity is detected at
concentrations lower than previously found.
“Say you’re dosing animals with a chemical
where, historically, an effect has not been
seen below a dose of ten milligrams per kilo-
gram,” Bus explains. “You do another study
and suddenly, you find a unique effect at one
milligram per kilogram. Under TSCA,
you’re  required to report that.” If such a
report were delayed because the significance
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Chemical conundrum. The EPA is moving cautiously toward
considering toxicogenomics data in chemical regulation.
Some companies will not test a drug
with a microarray experiment
that has any chance of becoming
part of a regulatory package.
And then there are companies who view
[submission of microarray data] as a
positive, who say the FDA gets more
information, we get more information,
and we might find a positive aspect to
our drug that we didn’t know about.
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of the microarray data wasn’t understood at
the time of testing, manufacturers could
conceivably face retroactive fines and penal-
ties. If penalties are levied per day and a sig-
nificant amount of time has passed, fines can
be substantial, says Bus. Under TSCA, the
EPA has the authority to levy fines of up to
$27,500 per day for nondisclosure of
required information.
Fine-tuning the Process
The FDA is working to alleviate some of
industry’s concerns. To facilitate its ability to
handle microarray data and keep approvals
moving, the agency has collaborated with pri-
vate firms on training exercises. Through a
material transfer agreement, Iconix has given
the CDER access to its proprietary relational
toxicogenomics database, DrugMatrix, for
evaluative and educational purposes, says
Karol Thompson, molecular toxicology team
leader in the CDER Division of Applied
Pharmacology Research. The DrugMatrix
database contains expression information
related to more than 600 substances, includ-
ing many approved medications. Iconix also
led two workshops on microarray technology
in February 2003 and January 2004 for mem-
bers of the Nonclinical Pharmacogenomics
Subcommittee of the CDER Pharmacology/
Toxicology Coordinating Committee. The
pharmacogenomics firm Gene Logic also has
provided the FDA with expression data from
its proprietary GeneExpress system database
as part of a collaborative project with CDER
research scientists and statisticians to identify
endogenous genes that can serve as indicators
of microarray sample quality.
In addition, the FDA worked with the
company Expression Analysis on a mock
submission using toxicology data developed
by Schering-Plough Corporation for a can-
didate drug that did not go on to clinical tri-
als. The submission included microarray
data, histology data, clinical chemistry data,
and phenotype data. The exercise served as a
practice run to help the FDA understand
the format and content of future drug sub-
missions containing microarray data. 
“I think the FDA, Expression Analysis,
and Schering-Plough gained a tremendous
amount from this collaboration,” says Steve
McPhail, CEO of Expression Analysis,
which provides commercial microarray
testing, analysis, and data management
services. “We gained a great perspective in
working with the FDA and in beginning to
understand their thinking on how this type
of data should be formatted for future reg-
ulatory submissions. And I think the FDA
gained value from the submission from our
experience with lots of clients and users of
data and the way that they need to become
prepared for submission.” 
Although regulators and industry are
working hard to hammer out the issues
around the submission of gene expression
data, such submissions are still somewhat
premature, says William Mattes, a researcher
on the HESI effort and senior scientific
director of toxicogenomics at Gene Logic.
For example, researchers and regulators have
not yet even decided how to report data.
The ultimate goal is to “submit data in some
tabular format that is computer-friendly and
will allow regulators to crunch the data, ana-
lyze it with software,” he says. “We have not
seen the FDA truly, openly discuss what
data standards would be. . . . The issue is
hugely in flux.” 
Mattes serves on a committee on phar-
macogenomics standards sponsored by the
Interoperable Informatics Infrastructure
Consortium, Health Level Seven, and the
Clinical Data Interchange Standards Consor-
tium, nonprofit organizations developing
data standards for health care and clinical tri-
als. According to Mattes, the joint committee
is discussing high-level questions regarding
the kind of data that should be included in
microarray submissions. Other groups are
promoting the use of specific data formats
such as the MIAME (Minimum Information
About a Microarray Experiment) standards
for content, as well as the accompanying
MAGE (MicroArray and Gene Expression)
data format standards developed by the
Microarray Gene Expression Data Society.
The European Bioinformatics Institute, the
NCT, and HESI have proposed definitions
for MIAME/Tox, which would add toxicoge-
nomics annotations to the basic MIAME
content framework.
Agreement on data formats will do
industry and regulators little good if experi-
mental protocols are weak or inconsistent.
The HESI studies found significant variation
among results of microarray experiments that
were  caused by differences in procedures
among participating laboratories, including
different operating procedures for isolating
and labeling mRNA samples, nonstandard
settings on hardware and software, and dif-
ferences in gene coverage and annotation
across different technology platforms.
Jarnagin and others say the standardization
problems found in the HESI experiments,
some of which were conducted 3–5 years
ago, are not as serious now. “There’s been
substantial advancement in the field in the
last few years,” says Jarnagin.
The quality and consistency of microar-
ray chips has improved since the HESI
experiments were conducted, agrees Brenda
Weis, who along with William Suk admin-
isters the Toxicogenomics Research Consor-
tium (TRC), a component of the NCT.
“The commercial products are particularly
good,” she says. “The manufacturing is at a
very high level.” 
Testing different microarray types was
an important part of initial standardization
experiments by the TRC, which involves
researchers at five academic centers across
the country, as well as the NIEHS Micro-
array Center. The consortium’s work builds
on the HESI studies by systematically
addressing different steps of the microarray
experiment to see where variability is most
likely to be introduced, says Weis. 
In the consortium’s first set of experi-
ments, reported in the March 2004 toxi-
cogenomics issue of EHP, the centers used
a total of 12 different microarray platforms.
In  the multifaceted experiments, all six
consortium centers used two common plat-
forms: an oligo microarray manufactured
at one of the centers and the commercial
Agilent mouse microarray platform, devel-
oped by TRC investigators working collab-
oratively with Agilent and the NCT
microarray resource contractor, Paradigm
Genetics. There were also 10 other “resi-
dent” cDNA- or oligo-based platforms that
were manufactured at and used by the indi-
vidual centers.
Other variables addressed in the experi-
ments have included the use of spike-in
RNA and RNA reference samples, known
sequences of RNA used as controls in
microarray experiments (spike-in RNA is
added to samples at a known concentration
whereas reference RNA is kept separate from
the samples but run through the same
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rather than a system where chemicals 
can be screened systematically.
–Linda Greer, Natural Resources Defense Councilmicroarray experiment). The goal was “to
see if they provided utility in helping us
understand how the different platforms per-
formed,” says Paules. 
There are still other aspects of microarray
analysis that can introduce variability into
results, according to Weis. During the TRC
studies, as during the HESI studies,
researchers found that the way each individual
center handled the RNA—including the
labeling of the samples, the hybridization and
wash conditions, and variables in the scan-
ning and analysis—all had an impact on the
eventual outcomes, says Paules. Results and
recommendations for improving standardiza-
tion have been submitted for publication. 
Now that studies have addressed the
technology, the consortium has begun
another series of experiments focusing on
the replication of genomic signatures. Each
center will receive common reference RNA
samples, Agilent microarray chips, and com-
pounds (acetaminophen and its nontoxic
isomer) to test using experimental animals.
All of the centers will use standardized pro-
tocols for the microarray analyses. The hope,
says Weis, is “to standardize the technical
aspects of the experiment in order to address
the issue of reproducibility of the biological
response across multiple research groups.
Whether or not we can do this successfully
is important information for the regulatory
community.”
Other groups that are studying method
standardization include the External RNA
Controls Consortium, a volunteer group
sponsored by the National Institute of
Standards and Technology. The group is
working to develop methods to evaluate the
performance of gene expression assays based
on the measurement of external RNA con-
trols, such as spike-in controls.
Standardization of animal models is
another concern in microarray experi-
ments. Researchers with the National
Toxicology Program (NTP), an intera-
gency organization based at the NIEHS,
are studying changes in microarray results
caused by homeostatic responses in Fisher
344 rats, one of the primary animal mod-
els used by the NTP. Results thus far, cur-
rently in press at Toxicologic Pathology,
show differences in microarray signatures
in samples taken from the left lobe of the
liver compared to those from the median
liver lobe of the same animal. 
“You may get the same overall story
from the two samples, but not the same
number of genes or the same intensity of
expression,” says Gary Boorman, a research
scientist with the NTP and the NIEHS
Environmental Toxicology Program, and a
coauthor of the forthcoming paper. These
results indicate that when labs coordinate
their efforts, they should not only look at
the technical issues, such as the microarray
platforms each group is using, but also make
sure that their methods for sampling animal
models are uniform, says Boorman.
The NTP group is also studying vari-
ables including the time of day that tissue is
collected, and the life stage and sex of the
animal. The goal is to describe how normal
variability in an animal strain can affect the
interpretation of studies using microarray
technology, says Nigel Walker, chair of the
NTP’s toxicogenomics faculty and a staff
scientist with the NIEHS Environmental
Toxicology Program. “We’re trying to define
‘normal,’” says Walker, “so we know when
the change in a gene is beyond the range of
normal physiological variability.”
The Burden of Interpretation
Once results of microarray experiments are
reproduced, scientists and regulators are still
faced with the difficulty of interpreting
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FDA Center for Drug Evaluation and Research (CDER)
The CDER reviews applications for new prescription and
over-the-counter drugs to ensure they been adequately
tested and are safe for human use. The CDER also moni-
tors drugs that are already on the market for unexpect-
ed health risks.
http://www.fda.gov/cder/
National Research Council (NRC) Committee on Emerging
Issues and Data on Environmental Contaminants 
This committee provides a public forum for government,
industry, environmental groups, and the academic com-
munity to discuss emerging evidence and issues in toxi-
cogenomics, environmental toxicology, risk assessment,
exposure assessment, and other related fields.
http://dels.nas.edu/emergingissues/index.asp
Microarray Gene Expression Data (MGED) Society
This international group of biologists, computer scien-
tists, and data analysts aims to facilitate microarray data
sharing by establishing standards for data annotation
and exchange, fostering the creation of microarray
databases and related software implementing these
standards, and promoting the sharing of high-quality,
well-annotated data within the life sciences community.
The group hopes to extend this mission to other
“omics” technologies.
http://www.mged.org/
GROUPS DOCUMENTS
Guidance for Industry: Pharmacogenomic Data Submission 
This guidance, issued by the FDA in draft form in November
2003, contains nonbinding recommendations on the submission
of pharmacogenomics data during the drug application process.
http://www.fda.gov/cder/guidance/index.htm
[select “Pharmacogenomic Data Submissions” under the heading “Procedural
(Draft)”]
Interim Policy on Genomics
This four-page policy paper outlines the EPA’s standing position on
the relevance and use of genomics technologies in risk assessment.
http://epa.gov/osa/spc/htm/genomics.pdf 
Mini-Monograph: Genomics and Risk Assessment
This mini-monograph published in the March 2004 toxicogenomics
issue of EHP includes recommendations for conducting studies and
handling data based on studies by the Health and Environmental
Sciences Institute/International Life Sciences Institute.
http://ehp.niehs.nih.gov/txg/docs/2004/112-4/toc.
html?section=toxicogenomics
Potential Implications of Genomics for Regulatory and Risk
Assessment Applications at EPA
This March 2004 draft white paper by the EPA examines the pos-
sible impact of genomics technologies on agency regulatory
activities.
http://www.epa.gov/osa/genomics-external-review-
draft.pdf
Regulatory Resourcesgenomic signatures. “There seems to be a
lack of consensus on how data should be ana-
lyzed,” says Timothy Zacharewski, an assis-
tant professor of biochemistry and molecular
biology at Michigan State University and a
member of the NRC committee. 
For example, although the FDA draft
guidance requires the submission of all data
on “known valid biomarkers,” the agency
currently does not recognize any genomic
signatures as valid biomarkers, according to
Leighton. “A lot of stuff has been published,
but not all of it is of the same quality, even
though it’s in the peer-reviewed literature,
either because of a small population study or
inadequate controls,” he says. 
The FDA draft guidance does not speci-
fy how genomic signatures are to be validat-
ed as biomarkers. “It’s an important issue,
and we’re discussing that,” says Leighton.
“In the near future, we may need to come
out with guidance on how to validate a
genomic signature.” However, he says he
doesn’t anticipate such guidance being
issued soon; the agency doesn’t want to act
in haste lest a less-than-optimal procedure
be institutionalized prematurely. 
There are logistical questions to consider.
“How do you validate a safety biomarker, say
for liver injury? You can’t run a clinical
trial where you cause liver injury,” says
Ulrich. Instead, scientists must compare
genomic signatures to traditional toxicity
tests using animals. But some traditional
biomarkers can be subjective and often
equivocal, says Ulrich. He cites the exam-
ples of alanine aminotransferase and aspar-
tate aminotransferase, biomarkers of liver
injury that also are occasionally associated
with muscle injury. “Weight lifters and
long-distance runners express [these
enzymes],” he says. “They’re subjective
biomarkers because they’re not liver-spe-
cific.” (Leighton notes, however, that the
biomarkers industry and academia rely
upon the most are less subjective. “Every
lab uses the same core set,” he says, “and
they’ve been in use for many years.”) 
Private companies have little motivation
to validate safety biomarkers, in part because
they don’t know how they’ll be used, says one
pharmaceutical representative who asked to
remain anonymous. “It’s expensive to validate
a genomic signature. And if we make the
investment and develop a better biomarker
for toxicity, all it will do is make it tougher to
get approvals.” As a result, the bulk of valida-
tion efforts probably will be conducted and
disseminated by nonprofit groups, academia,
and government labs.
One leader in this area is the NCT. In
addition to studies of experimental proto-
cols and replicability, the NCT is also
studying signatures generated by specific
exposures. The NCT’s Microarray Center
is focusing on liver toxicants such as aceta-
minophen [see “Phenotypic Anchoring:
Linking Cause and Effect,” EHP 111:
A338–A339 (2003)]. Other government
facilities are contributing as well. EPA
research into gene expression includes
studies of sentinel species such as amphib-
ians, fish, and aquatic microbes. The
Department of Energy is using microarray
experiments and other techniques to study
microbial communities used in the remedi-
ation of toxic waste. In the nonprofit
realm, the public ArrayExpress database of
expression data, managed by the European
Bioinformatics Institute, contains all the
results from the HESI experiments as well
as expression data from other studies.
There is also at least one commercial
company that is contributing to public
domain information on safety biomarkers.
In March 2004, Iconix announced plans to
publish five expression signatures of drug-
induced toxicity in the liver, kidney, and
heart. Information on one of the signa-
tures, for injury to renal tubules, was pre-
sented that month at the annual meeting
of the Society of Toxicology.
As industry and regulators wrestle with
the intricacies of microarray data formats
and submission, even more complex chal-
lenges loom: the data produced by proteo-
mics and metabolomics research. “We’re
well aware that metabolomic and proteom-
ic data might be more important in the
long term than the genomic data,” says
Leighton. Among other reasons, samples
are more readily available; it’s easier to
collect blood and urine than to take a liver
biopsy. “Then again,” says Zacharewski,
“with proteomics and metabolomics you
still have the problem of large, complex
data sets of which only a fraction can be
interpreted as being linked to any biolog-
ical effect.”
Issues of standardization and validation
will be similar for all of the “omics” tech-
nologies. So will tensions between con-
cerns of industry and statutory obligations
of regulators. That means many more
meetings between industry and agencies.
“We’re absolutely committed to not setting
standards in isolation,” says Benson. “It is
essential for the agencies to work together
and with industry and academia when
developing this regulatory framework.” 
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OTHER RESOURCES
ArrayExpress
This public database of expression data is managed by the European Bio-
informatics Institute. 
http://www.ebi.ac.uk/arrayexpress/ 
External RNA Controls Consortium Workshop: Specifications for
Universal External RNA Spike-In Controls
The External RNA Controls Consortium, sponsored by the National Institute
of Standards and Technology, has posted presentations from this bioinfor-
matics workshop on its website. The consortium is working to develop meth-
ods to evaluate the performance of gene expression assays based on the
measurement of external RNA controls.
http://www.cstl.nist.gov/biotech/workshops/ERCC2003/
MAGE (MicroArray and Gene Expression) 
This page of the MGED Society website provides MAGE-related links,
tools, and other resources.
http://www.mged.org/Workgroups/MAGE/mage.html
MIAME (Minimum Information About a Microarray Experiment) 
This page of the MGED Society website describes MIAME principles and
requirements, and lists links to relevant tools and news. Also includes a doc-
ument by the European Bioinformatics Institute, the NIEHS National Center
for Toxicogenomics, and the Health and Environmental Sciences Insti-
tute/International Life Sciences Institute in which these groups propose def-
initions for MIAME/Tox, which would add toxicogenomics annotations to
the basic MIAME content framework.
http://www.mged.org/Workgroups/MIAME/miame.html